NervGen Pharma readies trials for biologic treatment of spinal cord injury, Multiple Sclerosis - Becker's Orthopedic & Spine

NervGen Pharma readies trials for biologic treatment of spinal cord injury, multiple sclerosis  Becker's Orthopedic & Spine

NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and Multiple Sclerosis patients.

Northwestern University Stem Cell Therapy Clinic C...
Social Cognition: Does It Impact MS Symptoms?
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Monday, 30 March 2020

Captcha Image


 
 

Follow Us on Twitter

Follow Us On Twitter - Image